Cognition Therapeutics (CGTX) Retained Earnings (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Retained Earnings of -$203.2 million for Q1 2026, down 10.66% year-over-year from -$227.5 million in Q1 2025, and down 187.28% quarter-over-quarter from $232.8 million in Q4 2025.
Cognition Therapeutics (CGTX) Retained Earnings (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Retained Earnings for 7 consecutive years, with -$203.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 10.66% year-over-year to -$203.2 million; the TTM figure through Mar 2026 stood at -$203.2 million (down 10.66% YoY), while the FY2025 annual figure was $232.8 million, up 232.92% from the prior year.
- Retained Earnings slipped to -$203.2 million in Q1 2026 per CGTX's latest filing, from $232.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $232.8 million in Q4 2025 and bottomed at -$203.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$52.1 million across 5 years, with a median of -$115.4 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 76485.71% — and 2024, when it plunged 85266.33%.
- Cognition Therapeutics' Retained Earnings stood at -$115.4 million in 2022, then soared by 243.7% to $165.8 million in 2023, then sank by 205.63% to -$175.2 million in 2024, then soared by 232.92% to $232.8 million in 2025, then slumped by 187.28% to -$203.2 million in 2026.
- Business Quant data shows CGTX's Retained Earnings at -$203.2 million in Q1 2026, $232.8 million in Q4 2025, and -$195.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 240.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 240.08 Mn |
| Mar 31, 2026 | -203.22 Mn |
| Dec 31, 2025 | 232.83 Mn |
| Sep 30, 2025 | -195.30 Mn |
| Jun 30, 2025 | -190.37 Mn |
| Mar 31, 2025 | -183.64 Mn |
| Dec 31, 2024 | -175.16 Mn |
| Sep 30, 2024 | -167.32 Mn |
| Jun 30, 2024 | -157.38 Mn |
| Mar 31, 2024 | 179.16 Mn |
| Dec 31, 2023 | 165.83 Mn |
| Sep 30, 2023 | -196,000.00 |
| Jun 30, 2023 | -196,000.00 |
| Mar 31, 2023 | -121.57 Mn |
| Dec 31, 2022 | -115.40 Mn |
| Sep 30, 2022 | 149.72 Mn |
| Jun 30, 2022 | -103.59 Mn |
| Mar 31, 2022 | -197,000.00 |
| Dec 31, 2021 | -94.00 Mn |
| Sep 30, 2021 | -196,000.00 |